Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
1. Introduction
M/s. Sreepathi Pharmaceuticals Ltd. is located at Plot No. 163, Phase - V,
IDA Jeedimetla, RangaReddy District in Andhra Pradesh. Sreepathi
Pharmaceuticals Ltd. was established in 1986 and obtained Environmental
Clearance from MOEF vide Order Post Ex facto No J-11011/145/2005-IA
II (I), Dated August 11, 2005 to produce bulk drugs with a capacity of
13.5 TPM. The unit obtained change of product mix from state Pollution
Control Board in the year December 2010 with a vide letter No:
APPCB/HYD/JDM/289/CFE/HO-2010-2244. In order to meet the market
demand it is proposed to expand its capacity from the current 13.5 TPM
to 150 TPM using existing infrastructure.
A copy of the environmental clearance obtained from MOEF, Government
of India in 2005 and certified copy of compliance report obtained MOEF,
Government of India, Bangalore Regional office is enclosed at AnnexureI
1
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
2. Introduction of the Project
The salient features of the project are described in table below
TABLE 1
Salient Features of the Project
Location
Longitude and latitude
Year of establishment
Product category
Project category as per EIA
notification
Proposed Activity
Total investment on the plant
Total Investment on
Environmental Infrastructure
Total area of the plant
Total area of green belt
Water requirement
Source of water
Nearest habitation and distance
from the site
Nearest surface water bodies
Nearest reserve forest
Environmentally sensitive areas
within 10 km radius
Any national parks, wild life
sanctuaries within 10 km radius
Nearest air port and distance
Nearest railway station and
distance
Industrial Estates/Clusters in 10
KM radius
Nearest National Highway
Plot No. 163, Phase - V,
IDA Jeedimetla,
RangaReddy District
Andhra Pradesh.
17031’25.0” N Latitude and
78027’03.1” E Longitude
1986 and taken over the unit in 2006
5(F) Bulk Drugs & Intermediates
Category A (As the unit is located in 10Km radius
of Bollaram and Patancheru clusted which is
notified under CEPI)
Capacity expansion from 13.5 TPM to 150TPM
Current - Rs. 36.5 Crores & Proposed – Rs.10.0
Crores
Current - Rs.1.5 crores
Proposed - Rs. 2.15 Crores
10668.06 Sq.mts
3520.46 Sq. Mts
Total water requirement after expansion 190.79
KLD
Fresh water Requirement- 145.79 KLD
Recycled water- 45.0 KLD
Purchased from outside source through tankers
Shapurnagar(V) at a distance of 1.0 Km (SW)
Fox sagar – 1.27(E), Hussain sagar – 9.35
Kms(S)
Dulapalli reserve forest at a distance of 1.0Kms
in North direction
None
None
Rajiv Gandhi International Airport,Shamshabad is
nearly 40 Kms from the plant
Bharatnagar at a distance of 7.0Kms from the
plant
Chintal,Jeedimetla,Kajipalli
NH-7 3.11 Kms(E)
NH- 9 6.04 Kms(S)
2
Pre-Feasibility Report
i)
Sreepathi Pharmaceuticals Limited
Introduction of the company and proponent
Sreepathi Pharmaceuticals Ltd. was established in 1986 engaged in
manufacturing, developing and marketing of Bulk API'S (Bulk Active
Pharma Ingredients), Intermediates,
The management at Sreepathi Pharmaceuticals Ltd consists of highly
qualified and experienced personnel who have given the company the
edge in terms of quality, consistency, timely delivery and with cost
effective consciousness.
The company is headed by Mr. Srinivas Isola Managing Director, who has
taken over the company in the year of 2006. He is a Commerce graduate
and he is associated with his Father who is having enormous experience
in Chemical and process Industry more than 35 years. Under his able
management the company has seen enormous growth and development
and has continued to strive to enhance the Productivity.
The day-to-day operations at Sreepathi Pharmaceuticals are managed by
highly Qualified and Experienced Professionals with perfect blend for zeal
and
commitment.
The
Technical
Team
including
Research
and
Development activities are looked by technically experts with rich
experience in R&D and related activities
3
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
About the unit
M/s Sreepathi Pharmaceuticals Ltd. had taken over the existing unit in
2006 and obtained Environmental clearance from Ministry of Environment
to manufacture Bulk Drugs with a capacity of 13.5 TPM in the year 2005.
Quality
Management:
Strict
Manufacturing
Practices’
manufacturing
process
to
(GMP)
ensure
Quality
are
strict
control
integrated
adherence
measures,
Good
throughout
to
the
the
Quality
parameters for both in-process and finished products.

Manufacturing Facilities inspected and approved by Local Drug
authorities.

COS has been approved by EDQM.

WHO – GMP certification for Active Pharmaceutical Ingredients.
4
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
3. Project Description
3.1 Production Capacity
Currently the unit is permitted to manufacture 7 drugs in two groups with
a total capacity of 13.5 TPM any one group at a given point of time as
detailed below
TABLE 2
LIST OF EXISTING PRODUCTS
S.No
Name of the Product
Quantities in
TPM
1.
Group- A
Ciprofloxacin HCL
11.75
2.
Quinapyramine Sulphate
0.125
3.
Quinapyramine Chloride
0.125
4.
Enrofloxacin
TOTAL Group- A
1.5
13.5
Group - B
1.
Ciprofloxacin HCL
4.5
2.
Quinapyramine Sulphate
0.25
3.
Quinapyramine Chloride
0.25
4.
Enrofloxacin
1.5
5.
Norflaxacin
2.0
6.
Ofloxacin
3.0
7.
Sparfloxacin
2.0
TOTAL Group- B
13.5
Worst case scenario
13.5
5
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
3.1.1 Proposed expansion:
It is now proposed to expand the production capacity of the existing 7
products. Below Table provides list of products and proposed capacities.
TABLE 3
PROPOSED PRODUCTS & CAPACITY
Product Name
Production
Capacity
TPM
Product
Description
Drug/Intermediate
/Multipurpose
chemicals
1
Ciprofloxacin HCl
110.0
Bulk Drug
2
Enrofloxacin
25.0
Bulk Drug
3
Ofloxacin
3.0
Bulk Drug
4
Norfloxacin
5.0
5
Sparfloxacin
5.0
Bulk Drug
6
Quinapyramine Sulphate
1.0
Bulk Drug
7
Quinapyramine Chloride
1.0
Bulk Drug
S.No
Total
Bulk Drug
150.0
3.2 Manufacturing Process
Brief process description and process flow charts are given at Annexure
III
3.3 Raw Materials
List of raw material product wise is given at Annexure II
6
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
3.4 Water Requirement
The water requirement will be met from private suppliers through
tankers. The requirement for water in this unit is for process and domestic
purposes. The water balance for daily consumption is presented below.
TABLE
4.0
Water Balance– Current & Proposed
S.
No
Stream
1.
Process
2
Washings
Water
requirement in
KLD
Waste Water
discharge in KLD
Current After
Expansi
on
5.879
55.79
Current
After
Expans
ion
5.696
45.95
1.5
17.0
1.5
17.0
3
Boiler
4.0
65.0
1.15
6.5
4
Cooling
tower
4.0
25.0
1.0
0.5
5
DM Softener
--
2.0
--
2.0
6
RO
Back
washes
-
14.0
-
14.0
7
Domestic
2.0
5.0
1.5
4.0
8
Gardening
7.0
7.0
--
--
24.379
190.79
10.846
89.95
Total
Proposed
Method of
Treatment
and Disposal
MEE followed
by ATFD.
(Condensate
to ETP & RO)
ETP and RO
and re-use.
RO rejects to
MEE
ETP and RO
7
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
3.5 Wastes generation and control systems
3.5.1 Liquid Effluents
As detailed in table 4.0 waste water generation after expansion would be
89.95 KLD. It is proposed to segregate effluents into high COD and High
TDS stream and Low COD and Low TDS streams
High TDS and High COD stream would be treated in stripper followed by
MEE and ATFD.
The resultant sludge would be disposed to TSDF,
Hyderabad. The Low TDS stream would be treated along with MEE/ATFD
condensates in biological ETP followed by RO. The RO rejects would be fed
back to MEE.
The Permeate from RO would be used for cooling tower
make up. Thus the treatment system proposed is based on “Zero Liquid
Discharge” (ZLD) Concept
The schematic diagrams of ETP proposed are given in Figure 1.1 and
Figure 1.2 below
8
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.1
Schematic treatment scheme of high TDS effluents
Effluent from
Process and
Equalization
Tank
washings , Scrubber
R&D
Neutralization
Tank
Setting
Tank
Stripper
Aq. Distillate to
plants/TSDF Recovery
Cement
RO Reject
To TSDF
MEE
ATFD
Condensate to
Biological
Treatment
Condensate to Biological Treatment
SludgeTo TSDF
9
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.2 Low TDS Effluent Treatment System
Domestic effluent
Screen
Chamber
Effluents from utilities & MEE condensate
Screen
Chamber
Equalization
Tank
Neutralization
Tank
Clarifier
1
Aeration
Tank1
Aeration
Tank2
Clarifier
2
Holding
Tank
Sludge Holding
Tank
Sludge to TSDF
Sand
filter
Carbon
Filter
Filter Press
Sludge Cake
Permeate for re-use
RO
Ultra
filtration
Rejects to MEE
10
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
3.5.2 Solid wastes management
Hazardous and non - hazardous wastes generated from the proposed
expansion project are detailed below. Mode of disposal are also identified
and listed. Adequate storage of hazardous waste is ensured at the site
TABLE 5.0
Solid Wastes and Disposal
Quantity
S.N
o
Description
1
Spent Carbon
2
Distillation
bottom
Residue /
organic
residue
0.188
25.4
3
Inorganic
Residue
--
102.4
4
Evaporation
salts
2.750
159.0
As per
CFO TPM
0.382
After
Expansion
TPM
Remarks
4.23
5
ETP Sludge
0.250
0.350
6
Spent
paraffin
0.185
17.06
7
Spent
Piperazine ML
373.68
KL/Annum
6181.2
KL/Annum
8
Spent
N- Ethyl
piperazine ML
-
1443.6
KL/Annum
9
Detoxified
Container
and container
30Nos/
Month
100
Nos/Month
Sent to TSDF or Cement
Plants for co-processing
Sent to TSDF, Dundigal
Sent to TSDF, Dundigal
Authorized re-cyclers/
re-processors
Authorized re-cyclers for
recovery
Authorized re-cyclers for
recovery
After
Complete
detoxification it shall be
disposed to the outside
11
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
liners
agencies
10
Spent
lubricating oil
10 LPM
50LPM
11
Ash from
boiler
1.0 TPD
11.4 TPD
Authorized re-cyclers/
re-processors
Sold
to
manufactures
Brick
TSDF facility is about 12.0 KM from the site in Ranga Reddy District which
is created for catering the industries in this area. Transport of Hazardous
wastes to TSDF is done by the Ramkey. In case other hazardous wastes,
authorized recyclers will transport the wastes
4. Site Analysis
4.1 Plant Location
M/S Sreepathi Pharmaceuticals Ltd. is located at Plot No. 163, Phase - V,
IDA Jeedimetla, Ranga Reddy District in Andhra Pradesh. The site is
situated at 17031’25.0” N Latitude and 78027’03.1” E Longitude. The land
area of the plant is 1.113 acres. The nearest habitation from the site is
Shapurnagar(V) at a distance of 1.0 km. The nearest railway station
located at Bharatnagar at a distance of 7.0Kms from the Plant. There are
no ecologically sensitive areas like national parks, sanctuaries within 10
km radius of the site.
The site is surrounded by other industries of IDA Jeedimetla. Following
are the surroundings of the site
North – Natural Health Products
South – Road and Vijaya Industries
East –
Road and Substation
West -
Naala and Vacant land
12
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Following 8 reserve Forests are there within 10 KM radius of the site
Table 6.0
Reserve Forests in the study area
S.No
Reserve Forest
1
2
3
4
5
6
7
8
Dulapalli
GajulaRamaram
Suraram
Bowrampet
Pochampalli
Goudavalli
Dundigal
Kajipalli
Direction
Distance
from
the from
the
site
site
N
1.0
NW
3.07
NW
4.12
NW
4.9
N
5.2
N
6.7
NW
9.0
NW
12.0
Topo graphic features of the site and 10 KM study area and base map are
given at Fig 1.3 & 1.4.
Plant Photographs are given at Fig. 1.5
Site lay out map is given at Fig 1.6
13
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.3
Topo Sheet of the 10 KM study area
14
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.4
Base map of the study area
15
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.5
Plant & Green Belt Photographs
16
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Fig 1.6
Site lay out plan
17
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
5.0 Planning in Brief
The project is envisaged to be completed by December 2014, and the
production shall be initiated thereon.
Consultants are identified for
preparing the detailed project report.
6. Resource requirements
6.1 Power Requirement and Supply/Source
The total power requirement is 1250 KVA.
It shall be sourced from
APCPDCL and D.G sets as alternative to Power failure.
6.2 Production facilities , Utilities and effluent handling facilities
Apart from the existing facilities it is proposed to add additional
production facilities, utilities and effluents treatment infrastructure with
an additional investment of Rs. 10.0 Cores. The details are outlined in the
below table
TABLE 7.0
Production facilities/Utilities/ETP – Existing & Proposed
S.NO Details
Capacity/
No
After
Current Additions expansion
Production facilities
1
2
Production BlocksPharma/ Clean rooms
Utilities
Nos
Nos
3
4
5
6
8
9
10
11
12
Boiler ( coal Fired)
TPH
4
DG sets
KVA
1 X 320
Cooling tower
TR
1700
Softner/DM plant
M3/hour
5
Effluent handling & treatment facilities
collection tanks
KL
35
Effluent storage tanks
KL
15
Neutralisation tanks
KL
15
Stripper ,MEE,ATFD
KLD
-Biological treatment
KLD
--
13
RO plant
KL/ Hr
3
2
--
1
1
4
3
8
2 X 500
500
5
12
1320
2200
10.0
50
50
50
2 X 60
100
85
65
65
120
100.0
5.0
5.0
18
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
6.3 Land Requirement
The unit currently has 2.63 acres of land and out of which 3520.46 Sq.
mtrs of green belt is developed.
The land requirement for proposed
expansion activities will be 1954.94 Square Meters which can be met from
existing open area. Below table provides the land statement. Detailed site
lay out plan outlining current and proposed expansion activities is given at
Figure 1.5
Table 8.0
Land Statement
S.NO
1
2
3
4
5
Purpose
Built up area
Roads area
Green belt
Open area
Total
Area required for Proposed
expansion
Units
Sq.M
Sq.M
Sq.M
Sq.M
Sq.M
Sq M
Extent
3054.14
2138.52
3520.46
1954.94
10668.06
1954.94
7.0 Air Pollution
The Sources of air emissions from the plant are 4 TPH coal fired boiler &
proposed 8TPH coal fired boiler and additional DG sets
The process emissions from the second phase contain 2 No’s of scrubbers
are scrubbed with caustic lye and HCl separately and scrubbed waste
send to MEE. The other gases expected in the process are Carbon dioxide,
which are let out into atmosphere. Below Table gives current proposed
emission sources from the plant
19
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Table 9.0
Emission Source – Current & Proposed
S.No
Parameter
Capacity
Fuel
Anticipated
emissions
1
Existing
Process
---
--
2
Boiler stack
4 TPH
Coal
3
DG sets
1x 320
KVA
Diesel
SPM,SO2
&NOx
1
Proposed
(additions)
Boiler
8TPH
Coal
SPM,SO2
&NOx
2
DG set
2x 500
KVA
diesel
SPM, SO2,
NOX
3
Process
--
--
HCl, DMA,
SO2
HCl, DMA,
SO2
SPM,SO2
&NOx
Control
system
Scrubbed with
caustic lye/HCl
Stack Ht 30
meters,
Cyclone
separator
Stack Ht 3.5
mts, Acoustic
enclosures
Bag filter
&Stack Ht 30
meters
Stack height of
4.5 meters &
acoustic
enclosure
Scrubbed with
caustic lye/HCl
8.0 Bulk Chemical Storages:
Following bulk chemical storage facilities are proposed for expansion
activity
Table No 10.0
Storage facilities of bulk chemicals (Existing)
Sr
No
1
2
3
4
5
6
7
8
Capacity
(KL)
20
27
35
60
20
20
20
10
Name of the solvent
Acetic acid
Dil. Acetic acid
HCl
Methanol
DMS
Toluene
CS lye
N- Butanol
MOC
PP FRP
PP FRP
PP FRP
M.S
M.S
M.S
M.S
M.S
20
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
9.0. Project Financial
The estimated cost of the expansion project is approximately 10.0 Crores.
Out of this Rs. 2.15 Crores will be for effluents treatment facilities and
rest for other process equipment and safety equipment
Project cost
Rs. In
Crore
3.0 cr
2.8 cr
Total 5.8 cr
Plant& machinery + AHU+ Boiler
Civil & structural
Pipe lines & insulation
Electricals & instrumentation
Erection & commissioning &
painting
Safety & Environment
Furniture, fixtures, computers,
lighting etc
20% on plant &
machinery
10% on plant &
machinery
8% on plant &
machinery and
structures
0.60 cr
0.50 cr
0.40cr
2.15cr
Total
Contingencies & pre-operative
expenses
Project cost
0.10 cr
9.55 cr
0.45 cr
10.0 cr
21
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Annexure I
Copy of EC & Certified Compliance report from MOEF, Bangalore
22
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Annexure II
List of Raw Materials
23
Pre-Feasibility Report
Sreepathi Pharmaceuticals Limited
Annexure III
Typical Process description and flow sheets
24